Checkmate Pharmaceuticals Net Income

Checkmate Pharmaceuticals's net income stands at $-63M as of March 2022. That compares with $-43M in the prior-year period — down 46.1% year over year. That is below the Healthcare sector average of $16B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Checkmate Pharmaceuticals reported $-63M in net income versus $-43M a year earlier — a 46.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Checkmate Pharmaceuticals sits lower the Healthcare benchmark ($16B) with a net income of $-63M. That is roughly 100.4% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-43M in the prior-year period — down 46.1% year over year. Sustained growth in net income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Checkmate Pharmaceuticals's net income evolved across reporting periods, while the comparison chart places CMPI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.